Bionovo Announces First Quarter 2009 Highlights and Financi...(ar value 190000000 shares author...),Health

Date:5/7/2009

ar value, 190,000,000 shares authorized, 76,363,101 and 76,363,101 shares outstanding at March 31, 2009 and December 31, 2008, respectively 8 8 Additional paid-in capital 59,235 59,050 Accumulated other comprehensive gain 7 24 Accumulated deficit (44,118) (39,450) Total shareholders' equity 15,132 19,632 Total liabilities and shareholders' equity $17,667 $22,504 * The balance sheet at December 31, 2008 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

'/>"/>

SOURCE Bionovo, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial